Do you want to read an article? Please log in or register.
Combining immune checkpoint inhibitors with chemotherapy in advanced solid tumours: A review
Genitourinary CancerSkin Cancer
Related content
RECOMMENDED
Lung, Respiratory and Thoracic Cancer
Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis
Lung Cancer.
Dafni U, Tsourti Z, Vervita K, Peters S
doi: 10.1016/j.lungcan.
RECOMMENDED
Radio-Oncology
Prospective evaluation of the prognostic value of immune-related adverse events in patients with non-melanoma solid tumour treated with PD-1/PD-L1 inhibitors alone and in combination with radiotherapy
★ 1
Recommended by
Alexander Meisel, Faculty Member
Eur J Cancer.
Schweizer C, Schubert P, Rutzner S, Eckstein M, Haderlein M, Lettmaier S, Semrau S, Gostian AO, Frey B, Gaipl US, Zhou JG, Fietkau R, Hecht M
doi: 10.1016/j.ejca.2020.09.001.Visit the original publication at ncbi.nlm.nih.gov
Genitourinary Cancer
First-line immune-checkpoint inhibitor combination therapy for chemotherapy-eligible patients with metastatic urothelial carcinoma: A systematic review and meta-analysis
Eur J Cancer
Mori K, Pradere B, Moschini M, Mostafaei H, Laukhtina E, Schuettfort VM, Sari Motlagh R, Soria F, Teoh JYC, Egawa S, Powles T, Shariat SF, European Association of Urology–Young Academic Urologists Urothelial Carcinoma Working Group (EAU-YAU).
doi: 10.1016/j.ejca.2021.03.049
RECOMMENDED
Lung, Respiratory and Thoracic Cancer
Predictive impact of antibiotics in patients with advanced non small-cell lung cancer receiving immune checkpoint inhibitors : Antibiotics immune checkpoint inhibitors in advanced NSCLC
Cancer Chemother Pharmacol.
Schett A, Rothschild SI, Curioni-Fontecedro A, Krähenbühl S, Früh M, Schmid S, Driessen C, Joerger M
doi: 10.1007/s00280-019-03993-1.
Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis
JAMA Oncol.
Barroso-Sousa R, Barry WT, Garrido-Castro AC, Hodi FS, Min L, Krop IE, Tolaney SM
doi: 10.1001/
Lung, Respiratory and Thoracic CancerSkin Cancer
Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer
JAMA Oncol.
Mezquita L, Auclin E, Ferrara R, Charrier M, Remon J, Planchard D, Ponce S, Ares LP, Leroy L, Audigier-Valette C, Felip E, Zerón-Medina J, Garrido P, Brosseau S, Zalcman G, Mazieres J, Caramela C, Lahmar J, Adam J, Chaput N, Soria JC, Besse B
doi: 10.1001/
Further Publications
Association between immune-related adverse events and long-term survival outcomes in patients treated with immune checkpoint inhibitors
Eur J Cancer.
Maillet D, Corbaux P, Stelmes JJ, Dalle S, Locatelli-Sanchez M, Perier-Muzet M, Duruisseaux M, Kiakouama-Maleka L, Freyer G, Boespflug A, Péron J
doi: 10.1016/j.ejca.2020.03.017.
Genitourinary Cancer
Prognostic and Predictive Factors in Advanced Urothelial Carcinoma Treated with Immune Checkpoint Inhibitors: A Review of the Current Evidence
Cancers (Basel)
Rebuzzi SE, Banna GL, Murianni V, Damassi A, Giunta EF, Fraggetta F, De Giorgi U, Cathomas R, Rescigno P, Brunelli M, Fornarini G
doi: 10.3390/cancers13215517
Immune checkpoint inhibitors for metastatic bladder cancer
Cancer Treat Rev.
Massari F, Di Nunno V, Cubelli M, Santoni M, Fiorentino M, Montironi R, Cheng L, Lopez-Beltran A, Battelli N, Ardizzoni A
doi: 10.1016/j.ctrv.2017.12.007.